Tildrakizumab  (Synonyms: SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody)

Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (K_d: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis^[1][2][3].

IL-23^[1]

Tildrakizumab inhibits IL-23-induced STAT3 signaling in HeLa cells expressed the human IL-23Rα and IL-12Rβ1 receptors, with an IC₅₀ of 23 pM^[2].
Tildrakizumab reduces IL-23’s affinity for IL-23Rα through a negative allosteric modulation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tildrakizumab (100 mg/kg, s.c., every 2 weeks up to 9 months) is well tolerated in cynomolgus monkeys (toxicity studies)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

144.4 (kDa)

1326244-10-3

Liquid

Colorless to light yellow

[Tildrakizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.  [Content Brief]

  [2]. Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420.  [Content Brief]

  [3]. Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476.  [Content Brief]